- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.09. | INTEGRATED BIOPHARMA INC - 8-K, Current Report | 2 | SEC Filings | ||
| INTEGRATED BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 25.09. | Integrated BioPharma, Inc.: Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2026 | 565 | ACCESS Newswire | HILLSIDE, NJ / ACCESS Newswire / September 25, 2026 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter and fiscal year ended June 30, 2026.... ► Artikel lesen | |
| 20.08. | INTEGRATED BIOPHARMA INC - 8-K, Current Report | 1 | SEC Filings | ||
| 20.08. | Integrated BioPharma, Inc.: Integrated Biopharma's Wholly-Owned Subsidiary, Manhattan Drug Company, Inc. Appoints Michael Richtmyer as Head of Operations | 1.786 | ACCESS Newswire | HILLSIDE, NJ / ACCESS Newswire / August 20, 2026 / Integrated BioPharma, Inc. ((OTCQX:INBP)) - Manhattan Drug Company, Inc. ("MDC"), a wholly owned subsidiary of Integrated BioPharma, Inc. (the "Company")... ► Artikel lesen | |
| 02.07. | INTEGRATED BIOPHARMA INC - 8-K, Current Report | 1 | SEC Filings | ||
| 08.05. | Integrated BioPharma, Inc.: Integrated BioPharma Reports Results for its Quarter Ended March 31, 2026 | 497 | ACCESS Newswire | HILLSIDE, NJ / ACCESS Newswire / May 8, 2026 / Integrated BioPharma, Inc. ((OTCQX:INBP)) (the "Company" or "INBP") reports its financial results for the quarter ended March 31, 2026.Revenue for the... ► Artikel lesen | |
| 08.05. | INTEGRATED BIOPHARMA INC - 8-K, Current Report | 1 | SEC Filings | ||
| 08.05. | INTEGRATED BIOPHARMA INC - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 11.02. | Integrated BioPharma, Inc.: Integrated BioPharma Reports Results for Its Quarter Ended December 31, 2025 | 517 | ACCESS Newswire | HILLSIDE, NJ / ACCESS Newswire / February 11, 2026 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter ended December 31, 2025.Revenue for... ► Artikel lesen | |
| 10.11.25 | Integrated BioPharma, Inc.: Integrated BioPharma Reports Results for Its Quarter Ended September 30, 2025 | 355 | ACCESS Newswire | HILLSIDE, NJ / ACCESS Newswire / November 10, 2025 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter ended September 30, 2025.Revenue... ► Artikel lesen |
10 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 44,680 | +0,61 % | Community Rückblick: wO-User zum Kurssturz bei Newron Pharma: "Der Wirkstoff ist - Stand jetzt - tot" | © Foto: Newron Pharmaceuticals SpAFDA-Schock bei Newron Pharma: Nach dem Kurssturz entbrennt im wO-Forum eine hitzige Debatte über Todesfälle, Managementkommunikation und die Zukunft des Hoffnungsträgers... ► Artikel lesen | |
| TEVA PHARMACEUTICAL INDUSTRIES | 41,120 | 0,00 % | Teva Pharmaceutical Industries Ltd: Teva to Host R&D Day on Wednesday, November 11 in New York City | TEL AVIV, Israel, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it will host an R&D Day on Wednesday, November 11, 2026. At the R&D... ► Artikel lesen | |
| LB PHARMACEUTICALS | 36,650 | 0,00 % | LB Pharmaceuticals Inc: LB Pharmaceuticals to Participate in Upcoming Investor Events | ||
| MERCK KGAA | 143,95 | +0,49 % | Wer hat die Formel für die Abnehmspritze 2.0? Überholen BioNxt Solutions und Merck jetzt Novo Nordisk und Eli Lilly? Was macht BioNTech? | Der Boom bei Medikamenten gegen Übergewicht schafft innerhalb der Pharmabranche einen Milliardenmarkt mit einem Volumen von 100 Mrd. USD jährlich. Novo Nordisk und Eli Lilly kämpfen hier um die Vorherrschaft.... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 4,070 | +0,25 % | Aquestive Says FDA Accepts Anaphylm NDA Resubmission For The Treatment Of Type I Allergic Reactions | ||
| ETON PHARMACEUTICALS | 51,26 | -0,14 % | Eton Pharmaceuticals Lands Exclusive US Rights To Aquestive's Seizure Rescue Drug | ||
| NOVO NORDISK | 34,940 | -0,16 % | Novo Nordisk: Was hinter dem UBS-Urteil steckt | ||
| GENERATE BIOMEDICINES | 13,070 | +0,08 % | Generate Biomedicines Lands Major AI Drug Partnership to Target Booming Obesity Market | ||
| PFIZER | 26,170 | -0,30 % | Your gas station is selling Rhino, Anaconda and Magnum. It's really secret Viagra | ||
| KARDIGAN | 13,875 | -0,04 % | Kardigan stock initiated at Outperform by William Blair on pipeline | ||
| KAZIA THERAPEUTICS | 7,400 | 0,00 % | Kazia Therapeutics Limited: Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders | Clinical Milestone Expands Development of Paxalisib Beyond Oncology and Triggers $2 Million Payment to Kazia
SYDNEY, Sept. 22, 2026 /PRNewswire/ -- Kazia Therapeutics... ► Artikel lesen | |
| SCHOTT PHARMA | 24,900 | +1,43 % | DEUTSCHE BANK RESEARCH stuft Schott Pharma auf 'Hold' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat Schott Pharma von "Buy" auf "Hold" abgestuft, das Kursziel aber von 23 auf 25 Euro angehoben. Der Pharmazulieferer habe klare Fortschritte gemacht... ► Artikel lesen | |
| ELI LILLY | 1.117,40 | +0,07 % | Lilly wins EU backing for Foundayo weight-loss pill | ||
| YARROW BIOSCIENCE | 20,040 | +0,20 % | Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves Disease and Thyroid Eye Disease | Yarrow is advancing YB-101-a potential first-in-class anti-TSHR antibody, designed to directly disrupt the central mechanism driving both Graves' disease ("GD") and thyroid eye disease ("TED")
Dosing... ► Artikel lesen | |
| SANOFI | 71,79 | -0,84 % | 23,3 Milliarden US-Dollar für Neurologie: Wie Johnson & Johnson, AbbVie, Sanofi und NeuroThera um neue Hirnmedikamente ringen |
Das Unternehmen INTEGRATED BIOPHARMA INC kann der Branche Pharma zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INTEGRATED BIOPHARMA INC finden Sie auf Wallstreet Online.